<DOC>
	<DOCNO>NCT02672488</DOCNO>
	<brief_summary>Metformin widely use oral drug type 2 diabetes antitumor effect get much attention recently . It show metformin exerts anti-cancer activity several cancer , include primary liver cancer . In phase II study , safety efficacy combination metformin sorafenib evaluate patient advanced hepatocellular carcinoma .</brief_summary>
	<brief_title>Metformin Plus Sorafenib Advanced HCC</brief_title>
	<detailed_description>Sorafenib standard choice advance hepatocellular carcinoma ( BCLC-C ) , efficacy satisfy . Metformin widely use oral drug type 2 diabetes antitumor effect get much attention recently . It show metformin exerts anti-cancer activity several cancer , include primary liver cancer . Recent study suggest metformin treatment reduce risk HCC patient type 2 diabetes inhibit HCC invasion increase drug sensitivity sorafenib , however , safety efficacy combine therapy advance hepatocellular carcinoma remain unclear . In phase II study , patient advance hepatocellular carcinoma , measurable disease , Eastern Cooperative Oncology Group performance score≤1 enrol . Eligible subject randomly assign receive treatment sorafenib metformin plus sorafenib . The potential improvement overall survival , time progression safety evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Ability research subject authorize legal representative understand willingness sign write informed consent document 2 . Confirmed hepatocellular carcinoma accord one follow three criterion : histopathology , Two radiographic technique ( US , MRI , CT , Angiography ) confirm lesion typical arterial hypervascularization , Barcelona Clinical Liver Cancer stag C ( BCLCC ) 3 . Age &gt; 18 year old 4 . Patients liver disease classify Child Pugh class A 5 . Eastern Clinical Oncology Group ( ECOG ) performance status 0，1 2 ( Appendix I ) 6 . Hemoglobin ≥ 9 g/dL 7 . Absolute Neutrophil count（ANC）≥ 1,500 /mm3 8 . Platelet count≥ 50,000 /ul 9 . Total Bilirubin &lt; 2 mg/dL 10 . Transaminases ( SGOT SGPT ) 5 time upper limit normal 11 . Alkaline phosphatase &lt; 4 time upper limit normal 12 . Both men woman member race ethnic group eligible study 13 . Prothrombin time &gt; 50 % 或 PTINR &lt; 2.3 1 . Child Pugh Score 7 ascites 2 . Severe cardiovascular disease 3 . Uncontrollable hypertension 4 . History HIV infection 5 . Active clinical severe infection（ &gt; grade 2 ，NCICTCAE Version3.0） 6 . Women pregnant 7 . Administration systemic chemotherapy within last 6 month 8 . Presence History gastrointestinal bleeding randomization 9 . Epileptic seizure require drug therapy 10 . History allograft transplantation 11 . Patients sign bleed medical history 12 . Patients undergo kidney dialysis 13 . Metastatic liver cancer 14 . Uncontrollable ascites 15 . Encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>